Halaven FDA Approval History
FDA Approved: Yes (First approved November 15, 2010)
Brand name: Halaven
Generic name: eribulin mesylate
Dosage form: Injection
Company: Eisai Co., Ltd.
Halaven (eribulin mesylate) is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer, and liposarcoma.Breast Cancer; Liposarcoma
Development timeline for Halaven
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.